Dr. Takigiku is co-founder, President and CEO of Bexion Pharmaceuticals, Inc. Previously, he was at Procter & Gamble Pharmaceuticals, and was also interim co-Director of the Genome Research Institute (now the Reading Campus) of the College of Medicine, University of Cincinnati. Dr. Takigiku’s life-long research interests have been in the origin, evolution and sustainability of life. Early studies focused on paleoenvironmental studies involving elucidation of sedimentary isotopic and organic-geochemical records. Later work encompassed toxicology, pharmaceutical discovery and development, and consumer product innovation. Founding Bexion in 2006, the company now has a novel compound in clinical development for solid tumors, including glioblastoma multiforme, a deadly form of brain cancer. Dr. Takigiku received his undergraduate degrees from University of Colorado in Chemistry and Molecular Biology, his PhD in Chemistry from Indiana University, and business training from the Kellogg School of Management.